Induction in Medical Technology

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study ... overall survival, compared to those who received induction chemotherapy alone. "We are disappointed ...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... - Phase 3 study has demonstrated that induction Chemotherapy prior to ChemoRadiotherapy ... Cooperative Group (TTCC) announced today that induction Chemotherapy (IC) delivered prior to standard ... and throat. "This trial showed that adding induction Chemotherapy to ChemoRadiotherapy increased ...

St. Jude Finds More Than 100 Gene Variations Linked With Response to Leukemia Treatment

... of leukemic cells that survive after remission induction therapy -- the initial treatment. This ... less-toxic treatment, and also shows if remission induction therapy will likely fail. The researchers ... and an increased risk of high MRD at the end of induction therapy. "Our finding that IL15 plays such ...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

... are typically considered ineligible for standard induction chemotherapy. These data were presented today at ... cannot endure the toxic side effects of standard induction chemotherapy," said lead investigator, Amanda ... to minimize the risk of the disease progression. induction chemotherapy, the standard front-line AML ...

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months

... that achieved a complete remission (CR) after induction therapy has not yet been reached with an ... 409 patients who achieved a CR/CRu or PR after induction therapy. Patients that achieved a CR after induction therapy achieved a median PFS of >67 months ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... who are unlikely to benefit from standard induction chemotherapy. Many older AML patients cannot tolerate or do not respond well to standard induction chemotherapy. In Schedule A, 29 patients with a ... 17 percent, which compares favorably to standard induction chemotherapy. Infection was the most common ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

... (B-CLL). Leukine is indicated for use following induction chemotherapy in patients 55 years and older with ... factor approved in the U.S. for use following induction chemotherapy in older adults with acute ... of infections resulting in early death following induction chemotherapy in older adults with AML. ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... Study (Abstract #P277) A cost analysis for induction and maintenance dosing regimens for CIMZIA, ... that CIMZIA provided more cost savings during induction and maintenance phases of treatment when compared ... to infliximab. It consists of an open-label induction phase (400 mg of CIMZIA sub-cutaneously at Weeks ...

Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients

... information on the combination of Cloretazine and induction therapy in patients with unfavorable cytogenetics ... the addition of Cloretazine to a conventional induction regimen." The trial will be conducted in two ... in combination with standard induction therapy in previously untreated AML and high-risk ...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

... One patient died within 30 days of first induction treatment due to pneumonia. Dr. Ghulam Mufti, ... in this patient population. Patients received induction therapy of 600 mg/m2 of Cloretazine(R) (VNP40101M) in a thirty to sixty minute infusion. Second induction was permitted in patients with bone marrow ...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... The company is on track to report data from the induction phase of this trial in the fourth quarter of ... to induce a clinical response or remission. The induction phase of the study is followed by a four-week, ... response. The primary efficacy endpoint in the induction phase of the study is the attainment of ...

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

... unlikely to benefit from conventional 7+3 induction chemotherapy and provides support for the importance of assessing cytogenetics prior to induction treatment." "The positive results seen in this ... factors at baseline. Patients received an induction cycle of intravenous clofarabine administered as ...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

... and 8 CRp). 90% of responses occurred after first induction treatment. While follow-up is still ongoing, the ... patients was 3.2 months (0.1-16.4 months). The induction death rate within 30 days of first induction treatment was 14%. The majority of ...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

... Research Committee: Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus ... ovarian cancer (OC): Interim analysis of induction chemotherapy Melanoma -- William Stephenson, ... (AML) unlikely to benefit from standard induction chemotherapy Solid Tumors -- William ...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

... newly diagnosed multiple myeloma." Efficacy of induction with CyBorD in Newly Diagnosed Multiple ... and dexamethasone (PAD or VcDD) as induction Therapy Prior to Reduced Intensity ASCT Followed ... designed to evaluate the VELCADE combination as induction therapy prior to SCT in patients with ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... (CR) rates of 19 percent in the VcD arm as induction therapy and 35 percent post-transplantation. ... therapy now could be considered the standard induction treatment pre-transplant to which other regimens, ... A CR rate of 19 percent compared to 8 percent as induction therapy (p=0.0004) -- A CR rate of 35 ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... -- VELCADE Dexamethasone (Vc/D) versus VcAD as induction Treatment Prior to Autologous Stem Cell ... 31 May, 3:00 p.m. CT -- Efficacy of induction with CyBorD in Newly Diagnosed Multiple Myeloma ... and dexamethasone (PAD) as induction Therapy Prior to Reduced Intensity ASCT Followed ...

REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body

... the Study of Psoriasis with Infliximab [REMICADE] induction Therapy (SPIRIT), the European Infliximab ... at weeks 0, 2 and 6. Patients in the active induction treatment groups were randomized again at week 14 ... at the same dose administered during the induction phase. Patients in the placebo group were crossed ...

Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML

... is poorly tolerated in older patients and early induction mortality exceeds 30 percent in patients with ... thirty-day mortality rate. Patients receive an induction cycle of intravenous clofarabine administered as ... with at least one, but not more than two, prior induction regimens is underway. It is a randomized, ...

Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin

... intensified treatment with a higher fixed-dose induction of PEGASYS in combination with COPEGUS ... vs. eight percent). A pooled analysis of the induction dose arms vs. standard dose arms showed that treatment with higher fixed-dose induction for this difficult-to-treat patient ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... when added to cisplatin and 5- fluorouracil for induction therapy, significantly improved overall survival ... with cisplatin and 5-fluorouracil for the induction treatment of patients with locally advanced SCCHN ... cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... 2.5 mg/kg/day at week 26. The primary endpoint of SONIC was to assess the induction of steroid-free remission at week 26. Patients completing treatment ... every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... in colonoscopic evidence of improvement. These data, reported from the induction Stage of the ongoing PROTECT-1 trial, were presented at Digestive Disease ... in Crohn's disease over a combined total of 12 months. The induction Phase of the study is followed by a four-week, open label 'Active Period', ...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... the refill. Lialda is an FDA-approved, once-daily oral medication for the induction of remission in patients with active, mild to moderate ulcerative colitis ... Important Safety Information Lialda tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... is the only growth factor approved in the U.S. for use following induction chemotherapy in older adults (older than 55) with acute myelogenous ... to reduce the incidence of infections resulting in early death following induction chemotherapy in older adults with AML. Important Safety ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... stem cell transplantation." VELCADE-Dexamethasone versus VAD as induction Treatment Prior to ASCT in Newly Diagnosed Multiple Myeloma: Updated ... the Italian Myeloma Network GIMEMA, researchers compared VcTD with TD as induction therapy in preparation for and as consolidation after melphalan-based ...

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

... mg/kg through 30 weeks. The primary endpoint of SONIC was to assess the induction of steroid-free remission. Fifty-two percent of patients enrolled in SONIC ... every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE ...

CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)

... to focus on use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular ... ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. ...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... The favorable toxicology profile seen to date, coupled with the stable induction of interferon-alpha dependent responses when ANA773 is dosed every other ... observed with every-other-day dosing of ANA773 in monkeys included induction of interferon-alpha and interferon dependent responses at levels that are ...

Biopure Announces Meeting With FDA

... because of an expected 100% mortality within 6 months in the absence of induction chemotherapy. The purpose of the study would be to assess the efficacy of ... with red blood cells, as an adjunct to other special procedures, following induction chemotherapy for AML. A successful trial in this population could be ...

Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma

... Leukine is the only growth factor approved in the U.S. for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to ... to reduce the incidence of infections resulting in early death following induction chemotherapy in older adults with AML. Important Safety Considerations ...

Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

... we have presented for elesclomol, support our belief that oxidative stress induction is a promising new approach to cancer therapy in melanoma and, ... apoptosis and enhances the anticancer activity of paclitaxel through induction of oxidative stress. Poster presented at the International Conference ...

Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis

... Study to Evaluate Preferred induction Dosing Regimen SEATTLE, May 7 /PRNewswire-FirstCall/ -- Trubion ... 2b study of TRU-015 does not help the Company and Wyeth identify a TRU-015 induction dosing regimen or further establish the most effective treatment regimen ...

Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention

... H5N1 pandemic influenza vaccine. The ability of JVRS-100 to aid in the induction of a protective antibody response to the H5N1 vaccine at low doses of ... substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... a hallmark of drug-resistant tumors. Brostallicin was shown to affect DNA in both dividing and quiescent cells. Its actions can be followed by induction of a specific DNA binding protein foci that can be detected in circulating blood cells. Importantly, brostallicin was active in a ...

Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation

... The risk of relapse was determined by measurement of residual leukemia cells (so-called minimal residual disease) that were present after remission induction treatment. The measurement of minimal residual disease was used to modify therapy based on the level of disease detected. This measurement is the ...

Alfacell Provides Shareholder Update

... enhances effect of many types of anticancer drugs. The enhancement of the anticancer effectiveness by Onconase was shown to involve prevention of the induction defense mechanism which generally are triggered by the anticancer drugs and provide resistance to treatment. This propensity of Onconase makes it an ...

Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy

... from the Starzl Transplant Institute at the University of Pittsburgh Medical Center demonstrated the long-term safety and efficacy of alemtuzumab induction and tacrolimus monotherapy. (Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362LOGO ) Led by Dr. Henkie Tan, this group ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... therapy and for the treatment of adults with moderate to severely active rheumatoid arthritis. Cimzia (R) was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... Cristina Bautista, Michael Brown, Anita Kavlie, Connie Chang, Bruce Freimark. Peregrine Pharmaceuticals, Inc., Tustin, CA, Affitech AS, Oslo, Norway. induction of chemokines and cytokines by human phosphatidylserine antibody facilitates cell-mediated anti-tumor responses. In: Proceedings of the 100th Annual ...